Pulmocide
ID: 5871223Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
3
Funding Rounds
$152.8m
Money raised
Recent Funding Rounds
Overview
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
- Website:
- Headquarters: London
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company Pulmocide has raised a total of $122.4m in funding over 3 rounds.
Key Insights:
- Pulmocide Series C round, May 2021: $92m
- Pulmocide Series B round, March 2017: $30.4m
- Pulmocide funding round, March 2017: $30.4m
Industries
Pulmocide is active in the following industries: